Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.94 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.94 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.50 |
| ▸ | GGT1 | P19440 | 4/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL28238218 | 1.00 | PTGS1 (0.94) | PTGS1SLC7A11ENPEPGGT1GSR | |
| Cysteine SCHEMBL730594 | 1.00 | — | — | |
| Cysteine SCHEMBL1573764 | 1.00 | PTGS1 (0.94) | PTGS1SLC7A11ENPEPGGT1GSR | |
| Cysteine SCHEMBL18160 | 1.00 | — | — | |
| Cysteine SCHEMBL50242 | 1.00 | — | — | |
| Cysteine SCHEMBL17394843 | 1.00 | PTGS1 (0.94) | PTGS1SLC7A11ENPEPGGT1GSR | |
| Cysteine SCHEMBL16894009 | 1.00 | PTGS1 (0.94) | PTGS1SLC7A11ENPEPGGT1GSR | |
| Cysteine SCHEMBL16894007 | 1.00 | PTGS1 (0.94) | PTGS1SLC7A11ENPEPGGT1GSR | |
| Cysteine SCHEMBL50241 | 1.00 | — | — | |
| Cysteine SCHEMBL7610984 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8747825-B2 | Process for permanent shaping of human hair | KAO GERMANY GMBH (DE) | 2014-06-10 | — | — | US | claimed |
| CN-1846690-B | Emulsion medicine injection of propofol and preparation process thereof | SICHUAN KELUN PHARMACEUTICAL INDUSTRY CO LTD | 2013-04-03 | — | — | CN | claimed |
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| WO-2024112490-A2 | NITROSYL-HEME FORMULATIONS FOR THE TREATMENT CARDIOVASCULAR CONDITIONS, HEMOLYSIS, AND THE STABILIZATION OF CELL-FREE HEME MOLECULES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023196898-A1 | BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230183321-A1 | RCOM PROTEIN BASED CARBON MONOXIDE SCAVENGERS AND PREPARATIONS FOR THE TREATMENT OF CARBON MONOXIDE POISONING | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220401364-A1 | COMPOSITIONS OF FLUOROCARBON NANOEMULSION, AND METHODS OF PREPARATION AND USE THEREOF | NUVOX PHARMA LLC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220185867-A1 | MODIFIED HEMOGLOBIN MOLECULES AND USES THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-06-16 | — | — | US | disclosed |
| US-11304899-B2 | Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof | NUVOX PHARMA LLC (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210315978-A1 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | SHIRE-NPS PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-1714691-B1 | Method of removing carbon monoxide from an oxygen carrier such as hemoglobin and apparatus therefor | NIPRO CORP (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| EP-1555976-A4 | PROPOFOL WITH CYSTEINE | TRANSFORM PHARMACEUTICALS INC (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1555976-A2 | PROPOFOL WITH CYSTEINE | Transform Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040171691-A1 | Propofol with cysteine | TRANSFORM PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004039326-A2 | PROPOFOL WITH CYSTEINE | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401364-A1 | COMPOSITIONS OF FLUOROCARBON NANOEMULSION, AND METHODS OF PREPARATION AND USE THEREOF | PHOSPHO1, SGMS2, SGMS1 | PTGS1 1253/4885GRIN2D 4712/4885GRIN3B 4732/4885 |
| US-11304899-B2 | Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof | PHOSPHO1, SGMS2, SGMS1 | PTGS1 1253/4885GRIN2D 4712/4885GRIN3B 4732/4885 |
| US-20220185867-A1 | MODIFIED HEMOGLOBIN MOLECULES AND USES THEREOF | HBG1, HBG2, HBB | PTGS1 334/4885GRIN2D 2003/4885GRIN3B 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.